Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10562246
Filing Date		2003-06-24
First Named Inventor Steph		en John Martin Skinner
Art Unit		
Examiner Name		
Attorney Docket Numb	or	36697 16

					U.S.	PATENTS			Remove		
Examiner Initial*			Name of Pate of cited Docu	atentee or Applicant cument Pages, Columns, Lin Relevant Passages Figures Appear							
	1										
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion		ame of Patentee or Applicant Relev			Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publi				n information p		d button	Add		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	,	Kind Code <sup>4</sup>	Publication	Name of Patente Applicant of cited Document	e or  v	vhere Rel	or Relevant	T=
	1	95/28167	wo			1995-10-26	Research Corporat Technologies, Inc.	ion			
	2	96/40178	wo			1996-12-19	Research Corporat Technologies, Inc.	ion			Г
	3	01/52871	wo			2001-07-26	Diatranz Limited				

# Application Number 10562246 Filing Date 2003-06-24 Filing Named Inventor Stephen John Marfari Skinner Art Unit Examiner Name Attorney Docket Number 36697-16

									_			
	4	02/32	437	wo		2002-04-25	Diatra	anz Limited				
	5	03/0:	27270	wo		2003-04-03	Diatra	anz Limited				
If you wis	h to a	dd add	litional Foreign F	atent Document	citation	information p	lease	click the Add but	ton	Add		-
				NON-PATE	NT LITE	ERATURE DO	CUME	NTS		Remove		
Examiner Initials*	taminer Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andiror country where published.					Τs						
	1 CAMERON et al., "Formation of Insulin-Secreting, Seriol-Enriched Tissue Constructs By Microgravity Coculture of Isolated Pig Islets and Rat Seriol Cells," in Vitro Cellular & Developmental Biology, 37(8): 490-498, September 2001.											
If you wis	h to a	dd add	itional non-pater	nt literature docu	ment ci	tation informat	tion ple	ase click the Ad	d b	utton Ad	id	
				EX	AMINE	R SIGNATUR	RE					
Examiner	Signa	ture						Date Considered	П			
				lered, whether or								

See Kind Code of USPTO Patent Documents at invent USPTO\_GOLY or MPIP 901.04. 2 Enter office that issued the occument, by the hor-lefter office (WIPO) Standard ST3.) 3 For Lapraence patent counters, the ancidation of the parent of the register or the present be reset in unbelieved for patent document. 4 Kind of counterity by the appropriate symbols as andicated on the document under WIPO Standard ST1.6 if possible, 2 Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

Application Number		10562246			
Filing Date		2003-06-24			
First Named Inventor Steph		en John Martin Skinner			
Art Unit					
Examiner Name					
Attorney Docket Number		36697 16			

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.5	98 to make th	e appro	priate selection(s):	
---------------	----------	---------	---------------	---------	----------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e)(s).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Na Na-

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mark D. Moore/	Date (YYYY-MM-DD)	2006-12-05
Name/Print	Mark D. Moore, Ph.D.	Registration Number	42.903

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleater and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.